A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. Certain diseases and medical events can arise from the loss of critical cellular activity and lead to devastating or difficult-to-treat conditions or impairments. Our work is grounded in the emerging evidence that replacing or supporting those cells that have become dysfunctional or “lost” (destroyed or dead) can restore or replenish normal function and improve treatment and recovery paradigms. We call this approach “Replace and Restore”. We believe cellular therapies aimed at entirely replacing dysfunctional or destroyed cells may have more durable, broader, or suitable applicability than traditional pharmaceutical products, which often seek to affect just a single molecular target or group of biological pathways.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 9.5M | - | 15M | 0 |
| Net Income | -64M | -64M | -19M | -21M | -26M | -43M |
| EPS | $-0.28 | $-0.28 | $-0.09 | $-0.12 | $-0.15 | $-0.26 |
| Free Cash Flow | -19M | -19M | -24M | -29M | 646K | -24M |
| ROIC | -748.7% | -25.7% | -23.7% | -33.8% | -35.8% | -46.6% |
| Gross Margin | - | - | 96.5% | - | 95.0% | - |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | $0.00 |
| Operating Income | -37M | -37M | -21M | -25M | -23M | -49M |
| Operating Margin | 0.0% | - | -226.1% | - | -153.2% | - |
| ROE | -142.6% | -103.4% | -23.7% | -33.9% | -35.8% | -45.7% |
| Shares Outstanding | 227M | 227M | 207M | 179M | 175M | 165M |
Lineage Cell Therapeutics, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 95.8%. At current prices, the estimated annualized return to fair value is -30.2%.
Lineage Cell Therapeutics, Inc. (LCTX) has a 5-year average return on invested capital (ROIC) of -33.1%. This is below average and may indicate limited pricing power.
Lineage Cell Therapeutics, Inc. (LCTX) has a market capitalization of $343M. It is classified as a small-cap stock.
Lineage Cell Therapeutics, Inc. (LCTX) does not currently pay a regular dividend.
Lineage Cell Therapeutics, Inc. (LCTX) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Lineage Cell Therapeutics, Inc. (LCTX) generated $-19 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Lineage Cell Therapeutics, Inc. (LCTX) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Lineage Cell Therapeutics, Inc. (LCTX) reported earnings per share (EPS) of $-0.28 in its most recent fiscal year.
Lineage Cell Therapeutics, Inc. (LCTX) has a return on equity (ROE) of -103.4%. A negative ROE may indicate losses or negative equity.
Lineage Cell Therapeutics, Inc. (LCTX) has a 5-year average gross margin of 95.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for Lineage Cell Therapeutics, Inc. (LCTX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Lineage Cell Therapeutics, Inc. (LCTX) has a book value per share of $0.20, based on its most recent annual SEC filing.